Sun Pharma Share Price Slip Over 2% After USFDA Flags Baska Facility as OAI

Sun Pharmaceutical Industries share price declined over 2% on Thursday after the US Food and Drug Administration (USFDA) flagged one of the company’s facilities. The stock fell as much as 2.6% intraday to around ₹1,746, marking its sharpest single-day fall in nearly 3 months.

The stock was trading lower even as the benchmark Nifty 50 remained largely flat. Sun Pharma share price also hit their lowest level since mid-November.

USFDA Inspection Details

The USFDA conducted an inspection at Sun Pharma’s Baska facility between September 8 and September 19, 2025. Following the inspection, the regulator classified the outcome as Official Action Indicated (OAI), according to the company’s exchange filing.

Sun Pharma clarified that it continues to manufacture and supply approved products from the facility to the US market. The company said it will work closely with the regulator to address the observations and achieve full compliance.

Read More: Silver ETFs See Strong Gains in 2025 as UTI and ICICI Prudential Funds Lead the Rise.

Sun Pharma Financial Performance

Despite regulatory concerns, Sun Pharma reported stable financial performance. In Q2FY26, the company’s revenue rose nearly 9% year-on-year to ₹14,478 crore, while net profit increased 2.6% to ₹3,118 crore. Growth was driven by India and emerging markets, although US revenues declined by about 4%.

Conclusion

Sun Pharma’s stock reaction reflects short-term concerns after the USFDA’s OAI classification of its Baska facility. While regulatory issues may create near-term volatility, the company’s strong domestic business, speciality portfolio, and solid balance sheet continue to support its long-term growth story.

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.